These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

644 related items for PubMed ID: 19755624

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cutaneous reactions to epidermal growth factor receptor inhibitors.
    Pomerantz RG, Mirvish ED, Geskin LJ.
    J Drugs Dermatol; 2010 Oct; 9(10):1229-34. PubMed ID: 20941947
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinical management of EGFRI dermatologic toxicities: US perspective.
    Lacouture ME, Cotliar J, Mitchell EP.
    Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):17-21. PubMed ID: 18154214
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Clinical management of EGFRI-associated dermatologic toxicities: pharmacy perspective.
    Iacovelli L.
    Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):31-3. PubMed ID: 18154216
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Management of the cutaneous side effects of therapeutic epidermal growth factor receptor inhibition.
    Reck M, Gutzmer R.
    Onkologie; 2010 Oct; 33(8-9):470-9. PubMed ID: 20838065
    [Abstract] [Full Text] [Related]

  • 11. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
    Ocvirk J, Cencelj S.
    J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists.
    Hassel JC, Kripp M, Al-Batran S, Hofheinz RD.
    Onkologie; 2010 Apr; 33(3):94-8. PubMed ID: 20215799
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Toward evidence-based management of the dermatologic effects of EGFR inhibitors.
    LoRusso P.
    Oncology (Williston Park); 2009 Feb; 23(2):186-94. PubMed ID: 19323301
    [Abstract] [Full Text] [Related]

  • 18. Clinical management of EGFRI dermatologic toxicities: the Japanese perspective.
    Yamazaki N, Muro K.
    Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):27-8. PubMed ID: 18159648
    [Abstract] [Full Text] [Related]

  • 19. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy.
    Eilers RE, Gandhi M, Patel JD, Mulcahy MF, Agulnik M, Hensing T, Lacouture ME.
    J Natl Cancer Inst; 2010 Jan 06; 102(1):47-53. PubMed ID: 20007525
    [Abstract] [Full Text] [Related]

  • 20. Nail toxicity associated with epidermal growth factor receptor inhibitor therapy.
    Fox LP.
    J Am Acad Dermatol; 2007 Mar 06; 56(3):460-5. PubMed ID: 17147969
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.